After name change and dropped IPO, IN8bio tries again to boost its cancer pipeline

IN8bio has trod an unusual path to an IPO but now has revived its once-dropped attempt.

The phase 1 New York biotech made its first attempt at an IPO last year for $75 million but dropped its plans in November. Now, five months down the line, it’s trying again for the slightly lower amount of $69 million.